NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Forecast, Price & News

$1.80

+0.04 (+2.27%)

(As of 09/25/2023 ET)

Compare

Today's Range: $1.76
▼
$1.93
50-Day Range: $1.73
▼
$3.12
52-Week Range: $1.65
▼
$16.00

Volume: 29,032 shs
Average Volume: 57,997 shs
Market Capitalization: $3.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Agile Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 372.2% Upside
$8.50 Price Target
Short Interest: Healthy
0.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.59
Upright™ Environmental Score
News Sentiment: 1.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.05) to ($1.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Agile Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Agile Therapeutics has a forecasted upside of 372.2% from its current price of $1.80.
Amount of Analyst Coverage
Agile Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.58% of the float of Agile Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Agile Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Agile Therapeutics has recently decreased by 48.31%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Agile Therapeutics does not currently pay a dividend.
Dividend Growth
Agile Therapeutics does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agile Therapeutics is -1.59.

3.3

News and Social Media Coverage

News Sentiment
Agile Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Agile Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for AGRX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
3 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agile Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.50% of the stock of Agile Therapeutics is held by insiders.
Percentage Held by Institutions
Only 7.52% of the stock of Agile Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agile Therapeutics are expected to grow in the coming year, from ($6.05) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agile Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agile Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Price History

30 days | 90 days | 365 days | Advanced Chart

AGRX Stock News Headlines

September 24, 2023 | americanbankingnews.com

Maxim Group Upgrades Agile Therapeutics (NASDAQ:AGRX) to Buy

September 5, 2023 | finance.yahoo.com

Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 25, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

August 17, 2023 | msn.com

Agile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2

August 11, 2023 | finance.yahoo.com

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript

August 9, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023 | finance.yahoo.com

Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 26, 2023 | finance.yahoo.com

Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023

September 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

July 19, 2023 | finance.yahoo.com

This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys

July 18, 2023 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women

July 18, 2023 | msn.com

NASDAQ: $AGRX Biden's Executive Order Boosts Adoption Of Agile Therapeutics' Contraceptive Patch

July 14, 2023 | benzinga.com

Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women

July 11, 2023 | finance.yahoo.com

Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage

July 6, 2023 | fool.com

Agile Therapeutics (NASDAQ: AGRX)

June 30, 2023 | finance.yahoo.com

Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?

June 29, 2023 | benzinga.com

H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch

June 28, 2023 | finance.yahoo.com

The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care

June 27, 2023 | finance.yahoo.com

President Biden’s new executive order could help American women get better birth control

June 26, 2023 | benzinga.com

This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023

June 26, 2023 | finance.yahoo.com

Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members

June 23, 2023 | finance.yahoo.com

Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services

June 15, 2023 | finance.yahoo.com

Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health

June 14, 2023 | msn.com

Agile Therapeutics Rises on Teaming up with vitaCare for Expanding Twirla’s Reach

June 14, 2023 | finance.yahoo.com

Why Agile Therapeutics Stock Is Trading Higher Today

June 13, 2023 | finance.yahoo.com

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

June 8, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agile Therapeutics (AGRX), Check-Cap (CHEK) and Doximity (DOCS)

See More Headlines

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings: 8/09/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGRX
CUSIP: N/A
CIK: 1261249
Web: www.agiletherapeutics.com
Phone: (609) 683-1880
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +369.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($39.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,410,000.00
Net Margins: -201.02%
Pretax Margin: -116.82%
Return on Equity: -2,658.43%
Return on Assets: -192.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.76
Quick Ratio: 0.60

Sales & Book Value

Annual Sales: $10.88 million
Price / Sales: 0.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.83) per share
Price / Book: -0.27

Miscellaneous

Outstanding Shares: 1,930,000
Free Float: 1,916,000
Market Cap: $3.50 million
Optionable: Optionable
Beta: 1.13

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Alfred F. Altomari (Age 64)
Chairman, Pres & CEO
Comp: $644.4k

Mr. Geoffrey P. Gilmore (Age 57)
Sr. VP & Chief Admin. Officer
Comp: $478.92k

Dr. Paul Korner M.B.A. (Age 57)
M.D., Sr. VP & Chief Medical Officer
Comp: $480.4k

Mr. Scott M. Coiante (Age 56)
CFO, Sr. VP & Treasurer

Matthew Riley
Head of Investor Relations & Corp. Communications

Mr. Robert G. Conway M.E. (Age 65)
Sr. VP and Chief Corp. Planning & Supply Chain Officer

Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D. (Age 55)
M.P.H., Consultant

Ms. Amy Welsh (Age 52)
Sr. VP & Chief Commercial Officer

Joseph D'Urso
Controller

Key Competitors

View All Competitors

Institutional Ownership

State Street Corp
Bought 10,843 shares on 8/14/2023
Ownership: 1.095%

View All Institutional Transactions

AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.
What is Agile Therapeutics' stock price forecast for 2023?: 2 equities research analysts have issued 12-month target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 369.0% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.
How have AGRX shares performed in 2023?: Agile Therapeutics' stock was trading at $0.2270 at the start of the year. Since then, AGRX stock has increased by 698.3% and is now trading at $1.8122.
View the best growth stocks for 2023 here.
Are investors shorting Agile Therapeutics?: Agile Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 10,700 shares, a decrease of 48.3% from the August 15th total of 20,700 shares. Based on an average trading volume of 119,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the shares of the stock are short sold.
View Agile Therapeutics' Short Interest.
When is Agile Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AGRX earnings forecast.
How were Agile Therapeutics' earnings last quarter?: Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.48) by $0.38. The specialty pharmaceutical company earned $5.50 million during the quarter, compared to analysts' expectations of $4.68 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 201.02%.
When did Agile Therapeutics' stock split?: Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?: Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million.
What other stocks do shareholders of Agile Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).
What is Agile Therapeutics' stock symbol?: Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
Who are Agile Therapeutics' major shareholders?: Agile Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (1.10%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends.
How do I buy shares of Agile Therapeutics?: Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Agile Therapeutics' stock price today?: One share of AGRX stock can currently be purchased for approximately $1.81.
How much money does Agile Therapeutics make?: Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.50 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($39.56) on an earnings per share basis.
How can I contact Agile Therapeutics?: Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial